Diridavumab

Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]

Diridavumab
Monoclonal antibody
Type	?
Source	Human
Target	hemagglutinin
Clinical data
Other names	CR6261
ATC code	none
Identifiers
CAS Number	1393659-46-5
ChemSpider	none
Chemical and physical data
Formula	C₆₄₀₀H₉₉₃₄N₁₇₀₂O₁₉₉₆S₄₈
Molar mass	144.2 kg/mol g·mol⁻¹

This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.

References

World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab^†

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab^§ Exbivirumab^§ Foravirumab^§ Libivirumab^§ Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric ("-vixi-")	Cosfroviximab Larcaviximab Porgaviximab
Humanized ("-vizu-")	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab^§ Raxibacumab
Mouse ("-baco-")	Edobacomab^§
Chimeric ("-baxi-")	Pagibaximab^†
Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric ("-toxaxi-")	Obiltoxaximab
Humanized ("-toxazu-")	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.